GoodRx has expanded its Employer Direct platform to include Zepbound® (tirzepatide) KwikPen® at a fixed price of $449 for all doses, allowing self‑insured employers to subsidize the cost while the company captures a fee for facilitating the transaction.
The move reinforces GoodRx’s strategic pivot from a consumer discount model to a partnership‑based ecosystem. It adds a new revenue stream to the Pharma Direct segment, which grew 41% to $151.4 million in 2025, offsetting declines in prescription‑transaction revenue and supporting the company’s goal of returning to growth beyond 2026.
The partnership with Eli Lilly’s Employer Connect program positions GoodRx as a key facilitator of GLP‑1 drug access. The negotiated employer‑sponsored price of $449 contrasts with GoodRx’s own listed price of $995 for Zepbound, underscoring the value of the new offering to both employers and employees.
Management highlighted the initiative’s role in driving future growth. Wendy Barnes said, "We are confident that the actions we're taking today position us to return to growth beyond 2026, expand our role across the healthcare ecosystem, and create meaningful long‑term value for consumers, partners, and stockholders." Laura Jensen added, "Our collaboration with Lilly demonstrates how GoodRx connects manufacturer pricing and employer contributions in a single infrastructure. The result is a scalable model that expands access to Zepbound while supporting long‑term sustainability for employers."
The expansion is expected to strengthen GoodRx’s high‑margin Pharma Direct business, providing a scalable model that can be replicated across other high‑cost drugs and reinforcing the company’s long‑term durability in the growing GLP‑1 market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.